FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

- 1										
	OMB APPROVAL									
-1										
	OMB Number:	3235-0287								
	Estimated average b	urden								
1	hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Grant Jeremy T					<u>Th</u>	Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [TBPH] Inc. [TBPH] Inc. [TBPH]									k all applic Directo	able)	g Pers	on(s) to Issi 10% Ow Other (s below)	ner
(Last)	` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '				03/	U3/U6/2U24								Delow)			Delow)		
C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BLVD					4. l	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person					
(Street)	reet) OUTH SAN CA 94080													Form filed by More than One Reporting Person				ting	
FRANCISCO CA 94080				Rı	ule	10b5-1	1(c)	Trans	acti	on Ind									
(City)	(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												to	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Da			Code (Instr.					4 and Securitie Benefici Owned F		es For ally (D) Following (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) o (D)	r P	rice	Reported Transact (Instr. 3 a	ction(s)			Instr. 4)
Ordinary Shares 05/08/					8/202	3/2024			A		10,53	10,537 A		\$ <mark>0</mark>	22,	22,305		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution E if any (Month/Day	Date,	4. Transactio Code (Inst		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or	ount nber res					
Share Option (Right to Buy)	\$9.49	05/08/2024			A		23,576		(1)	0	5/07/2034	Ordinary Shares	23,	576	\$0	23,576	5	D	

Explanation of Responses:

1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

/s/ Brett A. Grimaud, Attorneyin-Fact

05/10/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.